Hormonal therapy for male breast cancer: A different approach for a different disease

Cancer Treatment Reviews

Volumn 32, Issue 2, 2006, Pages 101-105

  Nahleh, Zeina A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Hormonal; Male

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; AROMATASE; AROMATASE INHIBITOR; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; EXEMESTANE; FULVESTRANT; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ADRENALECTOMY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HYPOPHYSECTOMY; NONHUMAN; ORCHIECTOMY; PROGNOSIS; UNSPECIFIED SIDE EFFECT;

EID: 33644841769     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.12.007     Document Type: Review

References (58)

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 9 Regs Public-Use; November 2004 submission (1973-2002), National Cancer Institute, DCPPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
2. American Cancer Society: Cancer facts and figures 2005. Atlanta (GA): American Cancer Society; 2005.
3. S. Giordano D. Cohen A. Buzdar et. al. Breast carcinoma in men: A population-based study Cancer 101 1 2004 51-57
4. W.F. Anderson M.D. Althuis L.A. Brinton et. al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83 2004 77-86
5. L. Jardines B.G. Haffty J.H. Doroshow et. al. Breast cancer overview: risk factors, screening, genetic testing, and prevention R. Pazdur L.R. Coia W.J. Hoskins L.D. Wagman Cancer management: A multidisciplinary approach 7th ed. 2003 The Oncology Group New York 163-187
6. L. Brinton J. Lacey S.S. Devesa Epidemiology of breast cancer W.L. Donegan J.S. Spratt Cancer of the breast 5th ed. 2002 Elsevier Science United States of America 111-132
7. M.D. Tischkowitz S.V. Hodgson I.S. Fentiman Male breast cancer: aetiology, genetics, and clinical management Int J Clin Pract 56 10 2002 750-754
8. B. Cutuli M. Lacroze J.M. Dilhuydy et. al. Male breast cancer: Results of the treatment and prognostic factors in 397 cases Eur J Cancer 31A 1995 1960-1964
9. P.E. Goss C. Reid M. Pintilie et. al. Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996 Cancer 85 1999 629-639
10. D.B. Gough J.H. Donohue M.M. Evans et. al. A 50-year experience of male breast cancer: Is outcome changing? Surg Oncol 2 1993 325-333
11. K.S. Heller P.P. Rosen D. Schottenfeld et. al. Male breast cancer: A clinicopathologic study of 97 cases Ann Surg 188 1978 117-120
12. G. Ramantanis S. Besbeas J.G. Garas Breast cancer in the male: A report of 138 cases World J Surg 4 1980 621-623
13. G. Ribeiro R. Swindell M. Harris et. al. A review of the management of the male breast carcinoma based on an analysis of 420 treated cases Breast 5 1996 141-146
14. I.E. Young K.M. Kurian C. Annink et. al. A polymorphism in the CYP17 gene is associated with male breast cancer Br J Cancer 81 1999 141-143
15. H.S. Feigelson L.S. Shames M.C. Pike et. al. Cytochrome p450c17 α gene (CYP17) Cancer Res 58 1998 575-577
16. A.M. Dunning C.S. Healey P.D. Pharaoh et. al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer Br J Cancer 77 1998 2045-2047
17. J.R. Weiss K.B. Moysick H. Swede Epidemiology of male breast cancer Cancer Epidemol Biomarkers Prev 14 2005 20-26
18. I.E. Young K.M. Kurian M.a. Mackenzie et. al. The CAG repeat within the androgen receptor gene in male breast cancer patients J Med Genet 37 2000 139-140
19. C. Menin G.L. Banna G. De Salvo et. al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer Cancer Lett 168 1 2001 31-36
20. The CHEK2-Breast Cancer Consortium. Low penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics 2002;31:55-9.
21. S.H. Giordano A.U. Buzdar G.N. Hortobagyi Breast cancer in men Ann Int Med 137 2002 678-687
22. J. Wang-Rodriguez K. Cross S. Gallagher et. al. Male breast carcinoma: correlation of ER, PR, Ki-67, HER-2 Neu, and P53 with treatment and survival, a study of 65 cases Mod Pathol 15 2002 853-861
23. W.L. Donegan P.N. Redlich Breast cancer in men Surg Clin N Am 76 1996 343-363
24. W.L. Donegan P.N. Redlich P.J. Lang M.T. Gall Carcinoma of the breast in males: A multiinstitutional survey Cancer 83 1998 498-509
25. M.M. Munoz de Toro M.V. Maffini L. Kass et. al. Proliferative activity and steroid hormone receptor status in male breast carcinoma J Steroid Biochem Mol Biol 67 1998 333-339
26. K. Weber-Chappuis S. Bieri-Burger J. Hurlimann Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas Eur J Cancer 32 1996 1686-1692
27. D. Muir R. Kanthan S.C. Kanthan Male versus female breast cancers. A population-based comparative immunohistochemical analysis Arch Pathol Lab Med 127 2003 36-41
28. D. Rayson C. Erlichman V.J. Suman et. al. Molecular markers in male breast carcinoma Cancer 83 1998 1947-1955
29. M.D. Volm Male breast cancer Curr Treat Options Oncol 4 2003 159-164
30. J. Farrell F. Adair Effect of orchiectomy on skeletal metastases from cancer of the male breast Science 95 1941 654-657
31. I.A. Jaiyesimi A.U. Buzdar A.A. Sahin et. al. Carcinoma of the male breast Ann Int Med 95 1992 654-657
32. J.K. Patel T. Nemoto T.L. Dao Metastatic breast cancer in males: assessment of endocrine therapy Cancer 53 1984 1344-1346
33. G.G. Riberio The results of diethylstilbestrol therapy for recurrent and metastatic carcinoma of the male breast Br J Cancer 33 1976 465-467
34. M. Lopez L. DiLauro B. Lazzaro et. al. Hormonal treatment of disseminated male breast cancer Oncology 42 1985 345-349
35. M. Lopez A. Barduagni Cyproterone acetate in advanced male breast cancer Cancer 49 1982 9-11
36. F. Pannuti A. Martoni L. Busutti et. al. High-dose medroxyprogesterone acetate in advanced male breast cancer Cancer Treat Rep 66 1982 1763-1765
37. H. Kantarjian Y. Hwee-Yong G. Hortobagyi et. al. Hormonal therapy for metastatic male breast cancer Arch Int Med 142 1983 237-240
38. C. Doberauer N. Niederle C. Schmidt Advanced male breast cancer treatment with the LHRH analogue buserelin alone or in combination with the anti-androgen flutamide Cancer 62 1998 474-478
39. D.A. Vorobiof G. Falkson Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer Cancer 59 1987 688-689
40. G. Ribeiro Tamoxifen in the treatment of male breast carcinoma Clin Radiol 34 1983 625-628
41. G. Ribeiro R. Swindell Adjuvant tamoxifen for male breast cancer Br J Cancer 65 1992 252-254
42. M. Baum A.U. Buzdar J. Cuzick et. al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial Lancet 359 2002 2131-2139
43. J. Bonneterre B. Thurlimann J.F.R. Robertson et. al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen of arimidex randomized group efficacy and tolerability study J Clin Oncol 18 2000 3748-3757
44. J.M. Nabholtz A. Buzdar M. Pollak et. al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial J Clin Oncol 18 2000 3758-3767
45. D. Handesman Androgen actions and pharmacologic uses I.J. Detroit Endocrinology 2001 WB Saunders Philadelphia 2232-2242
46. K.J. Turner M. Morley N. Atanassova et. al. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility J Endocrinol 164 2 2000 225-238
47. W.E. Ellinwood D.L. Hess C.E. Roselli et. al. Inhibition of aromatization stimulates luteinizing hormone and testosterone secretion in adult male rhesus monkeys J Clin Endocrinol Metab 59 6 1984 1088-1096
48. M. Dukes P.N. Edwards M. Large et. al. The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033) - a potent, selective aromatase inhibitor J Steroid Biochem Mol Biol 58 4 1996 439-445
49. G. Shetty H. Krishnamurthy A.S. Bhatnagar et. al. Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata) Steroids 63 7-8 1998 414-420
50. P.E. Juniewicz J.E. Oesterling J.R. Walters et. al. Aromatase inhibition in the dog. I. Effect on serum LH, serum testosterone concentrations, testicular secretions and spermatogenesis J Urol 139 4 1988 827-831
51. C.E. Roselli J.A. Resko Sex differences in androgen-regulated expression of cytochrome P450 aromatase in the rat brain J Steroid Biochem Mol Biol 61 3-6 1997 365-374
52. A.L. Harris M. Dowsett R. Stuart-Harris et. al. Role of aminoglutethimide in male breast cancer Br J Cancer 54 1986 657-660
53. J.S. Patterson L.A. Battersby B.k. Bach Use of tamoxifen in advanced male breast cancer Cancer Treat Rep 64 1980 801-804
54. S.H. Giordano V. Valero A. Buzdar et. al. Efficacy of anastrozole in male breast cancer Am J Clin Oncol 25 2002 235-237
55. A. Italiano R. Largillier P.Y. Marcy et. al. Complete remission obtained with letrozole in a man treated with metastatic breast cancer Rev Med Int 25 2004 323-324
56. B.P. Zabolotny C.V. Zalal S.H. Meterissian Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer J Surg oncol 90 2004 26-30
57. A. Howell J.F. Robertson A. Quaresma et. al. Fulvestrant is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396-3403
58. http//www.cancer.gov/clinicaltrials/SWOG-SO511.